• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    11/14/24 4:00:06 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALV alert in real time by email
    SC 13G/A 1 kalv1015242sc13ga3.htm AMENDMENT NO. 3

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G/A

     

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    KalVista Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

     

     

    483497103

    (CUSIP Number)

     

     

     

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

     

    x       Rule 13d-1(c)

     

    ¨       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 10 pages 
     

     

    CUSIP No. 483497103

     

    13G/A Page 2 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    4,321,547

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    4,321,547

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,321,547

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.99%

     

    12

    type of reporting person

     

    OO

     

     

     Page 2 of 10 pages 
     

     

    CUSIP No. 483497103

     

    13G/A Page 3 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    4,321,547

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    4,321,547

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,321,547

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.99%

     

    12

    type of reporting person

     

    IN

     

     

     Page 3 of 10 pages 
     

     

    CUSIP No. 483497103

     

    13G/A Page 4 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*

    ( a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    3,366,547

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    3,366,547

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    3,366,547

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    7.78%

     

    12

    type of reporting person

     

    pN

     

     

     Page 4 of 10 pages 
     

     

    CUSIP No. 483497103

     

    13G/A Page 5 of 10 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS III, INC

     

    2 Check the Appropriate Box if a Member of a Group*

    ( a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    NEVADA

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    855,000

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    855,000

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    855,000

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    1.98%

     

    12

    type of reporting person

     

    CO

     

     

     Page 5 of 10 pages 
     

     

    CUSIP No. 483497103

     

    13G/A Page 6 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS IV, INC

     

    2 Check the Appropriate Box if a Member of a Group*

    ( a) o

    ( b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    NEVADA

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    100,000

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    100,000

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    100,000

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.23%

     

    12

    type of reporting person

     

    CO

     

     

     Page 6 of 10 pages 
     

     

    Item 1(a).Name of Issuer:

     

    KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    55 Cambridge Parkway, Suite 901E, Cambridge, MA 02142

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management and the Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc.; Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Partners III, Inc. (“Tang Capital Partners III”); and Tang Capital Partners IV, Inc. (“Tang Capital Partners IV”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    The address of Tang Capital Management, Kevin Tang and Tang Capital Partners is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of Tang Capital Partners III and Tang Capital Partners IV is 5955 Edmond Street, Las Vegas, NV 89118.

     

    Item 2(c).Citizenship:

     

    Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership. Tang Capital Partners III and Tang Capital Partners IV are Nevada corporations which are indirectly wholly owned by Tang Capital Partners.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 483497103

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Management. Tang Capital Management beneficially owns 4,321,547 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners, Tang Capital Partners III, Tang Capital Partners IV and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 4,321,547 shares of the Issuer’s Common Stock.

     

     Page 7 of 10 pages 
     

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners, Tang Capital Partners III, Tang Capital Partners IV and Tang Capital Management.

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 3,366,547 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Partners III. Tang Capital Partners III beneficially owns 855,000 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners III shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Partners IV. Tang Capital Partners IV beneficially owns 100,000 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners IV shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    The percentages used herein are based on 43,215,472 shares of Common Stock outstanding as of August 30, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on September 5, 2024.

     

    (b)Percent of Class:

     

    Tang Capital Management 9.99%
    Kevin Tang 9.99%
    Tang Capital Partners 7.78%
    Tang Capital Partners III 1.98%
    Tang Capital Partners IV 0.23%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Management 4,321,547 shares
    Kevin Tang 4,321,547 shares
    Tang Capital Partners 3,366,547 shares
    Tang Capital Partners III 855,000 shares
    Tang Capital Partners IV 100,000 shares

     

     Page 8 of 10 pages 
     

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Management 4,321,547 shares
    Kevin Tang 4,321,547 shares
    Tang Capital Partners 3,366,547 shares
    Tang Capital Partners III 855,000 shares
    Tang Capital Partners IV 100,000 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 9 of 10 pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: November 14, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL PARTNERS III, INC

     

    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  

     

     

    TANG CAPITAL PARTNERS IV, INC

     

    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 10 of 10 pages

     

     

     

    Get the next $KALV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KALV

    DatePrice TargetRatingAnalyst
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    1/7/2025$30.00Buy
    TD Cowen
    12/18/2024$22.00Buy
    BofA Securities
    3/11/2022$48.00 → $42.00Buy
    Needham
    12/10/2021$50.00 → $48.00Buy
    Needham
    More analyst ratings

    $KALV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JMP Securities initiated coverage on KalVista Pharmaceuticals with a new price target

    JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00

    1/31/25 7:03:28 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on KalVista Pharmaceuticals with a new price target

    TD Cowen initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $30.00

    1/7/25 7:55:33 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on KalVista Pharmaceuticals with a new price target

    BofA Securities initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $22.00

    12/18/24 7:36:39 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operations Officer Arif Bilal

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    10/8/25 6:59:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Arif Bilal

    3 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    10/8/25 6:58:37 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pereira Brian Jg

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    10/2/25 6:31:30 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    SEC Filings

    View All

    SEC Form 10-Q filed by KalVista Pharmaceuticals Inc.

    10-Q - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    11/10/25 4:45:53 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    11/10/25 4:35:12 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by KalVista Pharmaceuticals Inc.

    SCHEDULE 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/10/25 4:22:47 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    4/11/25 5:22:07 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/14/25 7:45:15 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $967,145 worth of shares (104,489 units at $9.26) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/11/25 7:51:08 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

    US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. "The US launch of EKTERLY is progressing with si

    11/10/25 4:30:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting

    KONFIDENT-S participants who switched to sebetralstat reported being very or extremely satisfied Interim results from KONFIDENT-KID show sebetralstat enables early, effective, safe treatment of HAE attacks in pediatric population and reveal higher attack frequency than previously believed KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced new patient satisfaction and pediatrics data from its clinical studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), as well as physician and patient survey and consensus study data highlighting the substantial unmet need for safe, effective and easy-to-use on-demand treatments, present

    11/6/25 8:01:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 8:40 a.m. EST Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 1:30 p.m. GMT The live audio webcast of each presentation will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available approximately two hours after the completion of the events. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedi

    11/5/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Leadership Updates

    Live Leadership Updates

    View All

    KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY," said Ben Palleiko, Chief Executive Officer of KalVista. "Their respective expertise in operations and human resources will be instrumental as we deliver on our commitment to people living with HAE." "I am excited to join KalVista and collaborate with such a talented team," said Mr. Arif. "This is a pivotal time for EKTERLY, and I am focused on strengthening the operational framework to ensure pe

    10/6/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig's appointment to the Audit Committee, Nancy Stuart will transition off the Audit Committee but remains a member of the Board and continues to serve on the Nominating and Corporate Governance Committee of the Board. The Board also approved Ms. Stuart's appointment to the Compensation Committee of the Board. "I am pleased to welcome Bethany to the Board of Directors of KalVista. Her extensive financial and operational experti

    10/2/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

    EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. "We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "Laurence's insight and counsel will be invaluable

    8/11/25 4:05:00 PM ET
    $KALV
    $MGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $KALV
    Financials

    Live finance-specific insights

    View All

    KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

    US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. "The US launch of EKTERLY is progressing with si

    11/10/25 4:30:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company's third quarter financial results and provide an operational update. The live audio webcast will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered

    11/3/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

    -EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms through August- -European Medicines Agency adopted a positive opinion recommending approval of sebetralstat and confirmed maintenance of orphan designation in EU; decision expected early October- -$191M in cash, providing runway into 2027- -Management to host conference call today at 8:30 a.m. ET- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fiscal quarter ended July 31, 2025. "This quarter marked a defining mome

    9/11/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 4:00:06 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 3:57:49 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

    SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 12:02:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care